Systematic bias in predictions of new drugs’ budget impact: analysis of a sample of recent US drug launches

Current Medical Research and Opinion

Budget Impact of Somatostatin Analogs (SSAs) as Treatment for Metastatic Gastroenteropancreatic Neuroendocrine Tumors (mGEP-NETs) in US Hospitals

European Neuroendocrine Tumor Society Conference
Budget Impact Model, Cancer, Economic Models, Gastroenterology, Neuroendocrine Tumors, Oncology

Economic Implications of Instituting Clinical Care Pathways in Metastatic Colorectal Cancer

AMCP Managed Care & Specialty Pharmacy Annual Meeting
Budget Impact Model, Cancer, Colorectal Cancer, Economic Models, Oncology

Cost–effectiveness of treatments for high-risk myelodysplastic syndromes after failure of firstline hypomethylating agent therapy

Expert Review of Pharmacoeconomics & Outcomes Research
Cancer, Cost Effectiveness Analysis, Economic Models, Hematology, Myelodysplastic Syndrome, Oncology

Cost-Effectiveness of Cetuximab as First-line Treatment for Metastatic Colorectal Cancer in the United States

American Journal of Clinical Oncology
Cancer, Colorectal Cancer, Cost Effectiveness Analysis, Economic Models, Oncology

Cost Effectiveness of Metal Stents in Pancreatic Cancer

ASCO Gastrointestinal Cancers Symposium
Cancer, Cost Effectiveness Analysis, Economic Models, Oncology, Pancreatic Cancer